Omeros Corp
OMER3.725USD
+0.115+3.19%
Horário de mercado （ET）Cotações atrasadas em 15 min
216.29MValor de mercado
PerdaP/L TTM
Mais detalhes de Omeros Corp Empresa
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Informações da empresa
Código da empresaOMER
Nome da EmpresaOmeros Corp
Data de listagemOct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
Número de funcionários202
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 08
Endereço201 Elliott Avenue West
CidadeSEATTLE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal98119
Telefone12066765000
Sitehttps://www.omeros.com/
Código da empresaOMER
Data de listagemOct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David J. Borges
Mr. David J. Borges
Chief Accounting Officer, Vice President - Finance, Treasurer
Chief Accounting Officer, Vice President - Finance, Treasurer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 17 de jul
Atualizado em: qui, 17 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
5.99%
Ingalls & Snyder LLC (Asset Management)
5.93%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
3.02%
D. E. Shaw & Co., L.P.
2.89%
Other
77.34%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
5.99%
Ingalls & Snyder LLC (Asset Management)
5.93%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
3.02%
D. E. Shaw & Co., L.P.
2.89%
Other
77.34%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
16.95%
Investment Advisor
15.51%
Hedge Fund
3.93%
Individual Investor
3.84%
Research Firm
3.66%
Bank and Trust
0.89%
Insurance Company
0.13%
Pension Fund
0.10%
Other
55.00%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
251
30.23M
45.04%
-382.24K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
2023Q2
303
29.52M
46.99%
+306.67K
2023Q1
308
23.79M
37.88%
-4.75M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
4.02M
6.87%
+58.15K
+1.47%
Mar 31, 2025
Ingalls & Snyder LLC (Asset Management)
3.98M
6.79%
-30.05K
-0.75%
Mar 31, 2025
The Vanguard Group, Inc.
3.24M
5.53%
+95.60K
+3.04%
Mar 31, 2025
Demopulos (Gregory A. M.D.)
2.03M
3.46%
--
--
May 23, 2025
D. E. Shaw & Co., L.P.
1.94M
3.31%
+99.63K
+5.42%
Mar 31, 2025
Stifel, Nicolaus & Company, Incorporated
1.56M
2.66%
-24.56K
-1.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.37M
2.34%
+29.70K
+2.22%
Mar 31, 2025
State Street Global Advisors (US)
1.36M
2.31%
+144.57K
+11.93%
Mar 31, 2025
Corient Private Wealth LLC
720.42K
1.23%
-13.03K
-1.78%
Mar 31, 2025
Nomura Securities Co., Ltd.
679.02K
1.16%
-68.26K
-9.13%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco NASDAQ Future Gen 200 ETF
0.44%
Vanguard US Momentum Factor ETF
0.12%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Invesco Dynamic Buyback Achievers ETF
0.01%
Ver Mais
Invesco NASDAQ Future Gen 200 ETF
Proporção0.44%
Vanguard US Momentum Factor ETF
Proporção0.12%
iShares Micro-Cap ETF
Proporção0.04%
ProShares Ultra Nasdaq Biotechnology
Proporção0.02%
Invesco Nasdaq Biotechnology ETF
Proporção0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
iShares Russell 2000 Growth ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
Invesco Dynamic Buyback Achievers ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
